All In Biotech

Free tool

FAERS Monitor: Transderm Scop

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017874 or its brand name (Transderm Scop, Scopolamine). Reports on generic versions are filed under their own applications.

Reports

5,759

Serious

3,941

68% of reports

Hospitalization

1,951

Death reported

765

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea711
  • off label use609
  • vomiting501
  • dizziness454
  • headache366
  • drug ineffective346
  • fatigue300
  • vision blurred279
  • death257
  • diarrhoea252
  • malaise252
  • confusional state243
  • pain241
  • dyspnoea207
  • dry mouth205

Reports by year received

View as table
YearReports
200432
200548
200660
200751
200892
200985
2010118
2011262
2012248
2013135
2014143
2015169
2016539
2017408
2018370
2019356
2020221
2021309
2022510
2023483
2024403
2025394
2026322

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,400 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dry mouthSignal2059.28.11,502
vision blurredSignal2797.46.61,554
confusional stateSignal2435.54.9895
vomitingSignal5013.93.61,098
dizzinessSignal4543.33.0754
nauseaSignal7113.33.11,169
off label useSignal6092.52.4592
headacheSignal3662.11.9226
malaiseSignal2522.11.9147
pain2411.41.332
diarrhoea2521.41.333
fatigue3001.41.336
dyspnoea2071.31.218
death2571.11.02
drug ineffective3461.00.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.